Efalizumab
As of the edition of 20 October 2026, Efalizumab is an antibody: withdrawn from the market in 2009; acts on ITGAL; US protection ended in 2015.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2009
- Kind
- Antibody
- Brand name
- Raptiva
- First approved
- 27 October 2003 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Roche
- Withdrawn from market
- 9 June 2009 (in some regions)
- Registered trials
- 39, 13 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Hormones; Nutrition and metabolism; Bones, joints and muscles; Eye
US protection
US protection ended in 2015.
US protection ended in 2015, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Roche. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Efalizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGAL | Integrin alpha-L | P20701 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 2 |
| Phase 1 | 7 | 5 | 0 | 2 |
| Phase 2 | 12 | 5 | 0 | 7 |
| Phase 3 | 8 | 7 | 0 | 1 |
| Phase 4 | 9 | 7 | 0 | 1 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant and Lead sponsor of trials | 2003 to now |